Clinical relevance of patient-reported outcomes: new threshold proven feasible in practice
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
2021-03-04
(Press-News.org) In order to show the clinical relevance of a difference between two treatment alternatives, in recent years, the manufacturer dossiers submitted in early benefit assessments of new drugs have increasingly contained responder analyses for patient-relevant outcomes. In such analyses, it is investigated whether the proportion of patients experiencing a noticeable change in the respective outcome differs between the two treatment groups in a study. This involves information on health-related quality of life or on individual symptoms such as pain or itching, which patients recorded with the help of scales in questionnaires.
But what difference makes a change relevant for the individual? That is, at what threshold can a response to an intervention be derived for the patient, so that, for example, the difference in the response rates of two groups can be used as an effect measure for early benefit assessments?
When is a difference relevant?
To answer this question, the methodological discussion has long revolved around so-called minimally important differences (MID). This approach is based on the idea that thresholds can be identified for the respective questionnaires that represent the smallest relevant change for patients. However, the methodological problems of this approach have recently become apparent. For instance, it has been shown that an MID is not a fixed value for a questionnaire, but is variable. It depends, for example, on the type and severity of a disease, the direction of a change (improvement or deterioration) or the methods used to determine it.
Furthermore, it has become clear that many scientific studies on the determination of an MID no longer meet today's methodological standards or that the methodology used is inadequately described in the scientific publications. In this situation, IQWiG has developed a new approach that makes it possible to easily determine thresholds delimiting a relevant range with sufficient certainty. The aim of this specification was also to create clarity for manufacturers and to make arbitrary responder analyses based on incomprehensible responder definitions unattractive.
Concerns were unfounded
From an evaluation of new scientific reviews on the topic, last year IQWiG therefore identified a value of 15% of the range of the respective scales as a plausible threshold for a relatively small, but sufficiently certain noticeable change. In its General Methods 6.0 published in November 2020, the Institute then specifically stated that in future assessments, it would use responder analyses from a threshold of at least 15% of the scale range of the measurement instrument used.
The strict stipulation of the 15% threshold for the acceptance of responder analyses in IQWiG assessments triggered discussions in the run-up to the General Methods 6.0. Among other things, some manufacturers feared that this approach would not be applicable to all scales and that proving the added benefit of a new drug would thus be made more difficult. On the occasion of the addenda published today on early benefit assessments of the drugs secukinumab (for psoriatic arthritis), ivacaftor (for cystic fibrosis) and alpelisib (for breast cancer), Katrin Nink from IQWiG's Drug Assessment Department emphasizes: "The concerns were unfounded. We see that the new threshold is suitable for use in practice." In the assessments in question, the manufacturers subsequently submitted the requested data so that the Institute could use the responder analyses for its assessments.
This applies to several questionnaires on both the burden of disease symptoms and on health-related quality of life in quite different indications such as cystic fibrosis in children, psoriatic arthritis or breast cancer. Nink further explains: "Based on analyses with the new response thresholds, we were able to show the advantages and disadvantages of treatments, such as the advantage of ivacaftor for the quality of life of children with cystic fibrosis. So the new generic criterion works."
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2021-03-04
A deep sequencing study of 747 SARS-CoV-2 virus isolates has revealed mutant peptides derived from the virus that cannot effectively bind to critical proteins on the surface of infected cells and, in turn, hamper activation of CD8+ killer T cells that recognize and destroy these infected cells. These peptides, the authors say, represent one way the coronavirus subverts killer T cell responses and stymies immunity in the host. Their results may be of particular importance for SARS-CoV-2 subunit vaccines, such as the RNA vaccines currently in use, which induce responses against a limited number of viral ...
2021-03-04
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing of already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development. The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells. However, it was previously unknown whether SARS-CoV-2 can use TMPRSS2-related proteases for cell entry and whether these proteases can be blocked by Camostat. Moreover, it was unclear whether metabolization of Camostat interferes with antiviral activity. An international team of researchers around Markus Hoffmann and Stefan Pöhlmann ...
2021-03-04
Solving a Genetic Mystery at the Heart of the COVID-19 Pandemic
As the COVID-19 pandemic enters its second year, scientists are still working to understand how the new strain of coronavirus evolved, and how it became so much more dangerous than other coronaviruses, which humans have been living alongside for millennia.
Virologists and epidemiologists worldwide have speculated for months that a protein called ORF8 likely holds the answer, and a recent study by Berkeley Lab scientists has helped confirm this hypothesis.
In a paper published in mBio, lead author Russell Neches and his colleagues ...
2021-03-04
By embedding a silver catalyst inside a porous crystal, KAUST researchers have improved a chemical reaction that converts carbon dioxide (CO2) into carbon monoxide (CO), which is a useful feedstock for the chemical industry.
Carbon monoxide is a building block for producing hydrocarbon fuels, and many researchers are searching for ways to produce it from CO2, a greenhouse gas emitted by burning fossil fuels. One strategy involves using electricity and a catalyst to drive a so-called CO2 reduction reaction. But this reaction typically produces a variety of other products, including methane, methanol and ethylene. Separating these products significantly raises the cost of the process, ...
2021-03-04
A study on big droughts in the Greater Mekong region revealed findings that can help reduce the carbon footprint of power systems while providing insights into better designed and more sustainable power plants.
The study, titled 'The Greater Mekong's climate-water-energy nexus: how ENSO-triggered regional droughts affect power supply and CO2 emissions', was published by researchers from the Singapore University of Technology and Design (SUTD) and the University of California, Santa Barbara, in the journal Earth's Future.
Known as an important means to support economic growth in Southeast Asia, the hydropower resources of the Mekong River Basin have been largely exploited by the riparian countries. The researchers ...
2021-03-04
The current commercial production of methanol through the hydrogenation of the green-house gas CO2 relies on a catalyst consisting of copper, zinc oxide and aluminum oxide. Even though this catalyst has been used for many decades in the chemical industry, unknowns still remain. A team of researchers from the Interface Science Department of the Fritz-Haber-Institute of the Max Planck Society, the Ruhr-University Bochum, Stanford Linear Accelerator Center (SLAC), FZ Juelich and Brookhaven National Laboratory have now elucidated the origin of intriguing catalytic activity and selectivity trends of complex nanocatalysts ...
2021-03-04
In 2015, hackers infiltrated the corporate network of Ukraine's power grid and injected malicious software, which caused a massive power outage. Such cyberattacks, along with the dangers to society that they represent, could become more common as the number of cyber-physical systems (CPS) increases.
A CPS is any system controlled by a network involving physical elements that tangibly interact with the material world. CPSs are incredibly common in industries, especially those integrating robotics or similar automated machinery to the production line. However, as CPSs make their way into societal infrastructures such as public transport and energy management, it becomes even more important to ...
2021-03-04
A research review led by Oxford Brookes University has found a large proportion of COVID-19 survivors will be affected by neuropsychiatric and cognitive complications.
Psychologists at Oxford Brookes University and a psychiatrist from Oxford Health NHS Foundation Trust, evaluated published research papers in order to understand more about the possible effects of the SARS-COV-2 infection on the brain, and the extent people can expect to experience short and long-term mental health issues.
Patients experienced a range of psychiatric problems
The study found that in the short term, a wide range of neuropsychiatric problems were reported. In one examined study, 95% of clinically ...
2021-03-04
As millions of Fantasy Premier League players mull over a decision whether to start Bruno Fernandes or Mohamed Salah in their teams this weekend, new research by the University of Limerick in Ireland has unlocked the secrets of the popular online game.
A new study by a team of researchers at UL has identified the underlying tactics used by the top-ranked competitors among the seven million players of Fantasy Premier League (FPL), the official - and world's largest - fantasy football game of the English Premier League.
Joseph O'Brien, Professor James Gleeson, and Dr David O'Sullivan, based within the ...
2021-03-04
With three out of four newly emerging infectious human diseases originating in animals*, there is an urgent need to monitor the legal trade in wildlife, according to new research by Vincent Nijman, Professor in Anthropology at Oxford Brookes University.
Professor Nijman, who has been involved in monitoring and regulating the legal wildlife trade for over two decades, said: "Covid-19 more than anything else has put a spotlight on emerging infectious diseases and how this is linked to the trade in wild animals. Few people are aware of its scale. With literally hundreds of millions ...
LAST 30 PRESS RELEASES:
[Press-News.org] Clinical relevance of patient-reported outcomes: new threshold proven feasible in practice
Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.
